Vas Narasimhan is the CEO of Novartis AG, the Swiss multinational pharmaceutical corporation headquartered in Basel, Switzerland. Appointed CEO in February 2018 at the age of 41, Narasimhan became one of the youngest-ever leaders of a top-10 global pharma company. Born in Pittsburgh to Indian-American parents from Tamil Nadu, he holds both an M.D. from Harvard Medical School and a Master of Public Policy from Harvard Kennedy School. Under his leadership, Novartis has transformed into a pure-play innovative medicines company and delivered record-breaking financial performance, with net sales reaching $54.5 billion in 2025 and core operating margins hitting 40%.
Read on to discover Novartis CEO email address, Vas Narasimhan net worth in 2026, salary and compensation, career history, wife & family, and more.
Vas Narasimhan – Quick Facts
| Vas Narasimhan — At a Glance | |
|---|---|
| Full Name | Vasant “Vas” Narasimhan |
| Position | CEO, Novartis AG |
| Company | Novartis AG (SIX: NOVN / NYSE: NVS) |
| Age | 49 years old (born August 26, 1976, Pittsburgh, PA) |
| Education | B.S. Biological Sciences, University of Chicago; M.D., Harvard Medical School; M.P.P., Harvard Kennedy School |
| CEO Since | February 2018 |
| 2025 Compensation | CHF 24.9 million (~$32.4 million) |
| Estimated Net Worth | $50–70 million (2026 est.) |
| Spouse | Srishti Gupta (married 2003) |
| Recognition | TIME100 Most Influential People in Health (2025) |
| Headquarters | Basel, Switzerland |
Career Highlights
- Youngest major pharma CEO: Appointed Novartis CEO at age 41, one of the youngest-ever leaders of a top-10 global pharmaceutical company
- Sandoz spin-off: Led the strategic separation of Sandoz (generics division) in October 2023, transforming Novartis into a focused innovative medicines company
- Record financial performance: Achieved $54.5 billion in net sales (2025), with 40% core operating margins — the highest in the company’s history
- Pipeline growth: Oversaw key drug approvals and growth in Kisqali (+44%), Pluvicto (+70%), and Scemblix (+87%) in 2025
- AI in pharma: Championed AI-driven drug development at Novartis, predicting major payoffs for pharma in 7–10 years
- TIME100 Health: Named to TIME100 Most Influential People in Health in 2025
Vas Narasimhan Net Worth & Salary
As of 2026, Vas Narasimhan’s estimated net worth is approximately $50–70 million, based on his accumulated compensation, equity holdings, and investments over his career at Novartis. His 2025 total compensation of CHF 24.9 million (~$32.4 million) represented a 30% increase over the prior year, driven largely by record payouts from Novartis’s long-term performance plan.
CEO Compensation Breakdown (2025)
| Component | Amount (CHF) | Amount (USD est.) |
|---|---|---|
| Base Salary | CHF 1.90M | ~$2.5M |
| Short-Term Incentive | CHF 3.60M | ~$4.7M |
| Long-Term Performance Plan | CHF 17.30M | ~$22.5M |
| Other Benefits | CHF 2.10M | ~$2.7M |
| Total Compensation | CHF 24.9M | ~$32.4M |
Key Insight: Narasimhan’s long-term performance plan payout increased by CHF 4.8 million in 2025, with the 2023–25 cycle vesting at 188% of target — the highest level since he became CEO in 2018. This reflects Novartis’s exceptional stock performance and operational results.
Novartis Financial Summary
Novartis AG is one of the world’s largest pharmaceutical companies. Under CEO Vas Narasimhan, the company has delivered consistent growth as a pure-play innovative medicines business following the Sandoz spin-off in October 2023.
Novartis Financial Performance (FY2025 vs. FY2024)
| Metric | FY2025 | FY2024 | YoY Change |
|---|---|---|---|
| Net Sales | $54.5B | $50.3B | ▲ +8% (cc) |
| Core Operating Income | $21.9B | $18.8B | ▲ +12% (cc) |
| Core Operating Margin | 40.1% | 37.4% | ▲ +1.4pp |
| Core Net Income | $17.4B | — | ▲ +11% (cc) |
| Core EPS | $8.98 | — | ▲ +15% (cc) |
| Free Cash Flow | $17.6B | $16.3B | ▲ +8% |
| Employees | ~77,000 | ~78,000 | — |
Growth Drivers (2025): Kisqali (+44% cc), Kesimpta (+27% cc), Pluvicto (+70% cc), Scemblix (+87% cc), and Cosentyx (+11% cc) were the key growth drivers behind Novartis’s record 2025 performance. The company reached approximately 300 million patients globally.
Novartis Competitors
Novartis operates in the highly competitive global pharmaceutical industry. Key competitors include:
- Roche — Swiss pharma rival; leader in oncology and diagnostics
- Pfizer — Global pharma giant with diverse therapeutic portfolio
- Johnson & Johnson — Diversified healthcare with strong pharma division
- AbbVie — Focused on immunology and oncology (Humira, Skyrizi)
- Merck & Co. — Major player in oncology (Keytruda) and vaccines
- AstraZeneca — Fast-growing oncology and rare disease portfolio
- Sanofi — French pharma with strength in immunology and vaccines
- Eli Lilly — Leader in diabetes and obesity treatments (Mounjaro)
Novartis CEO Email Address & Contact
Below are the official contact details for Novartis and CEO Vas Narasimhan:
| Contact Information | |
|---|---|
| Corporate Headquarters | Forum 1, Novartis Campus, CH-4056 Basel, Switzerland |
| Phone | +41 61 324 1111 |
| Investor Relations Email | [email protected] |
| Website | novartis.com |
| Vasant Narasimhan — CEO, Novartis | |
| Stock Ticker | SIX: NOVN / NYSE: NVS |
Career & Education – Company, University, & College
Vas Narasimhan’s career spans medicine, public policy, management consulting, and pharmaceutical leadership. His unique dual training in medicine and public policy has shaped his approach to running one of the world’s largest pharma companies.
Career Timeline
| Period | Role | Organization |
|---|---|---|
| 1993–1997 | B.S. Biological Sciences | University of Chicago |
| 1999–2003 | M.D. / M.P.P. (dual degree) | Harvard Medical School / Harvard Kennedy School |
| ~2004 | Management Consultant | McKinsey & Company |
| 2005 | Joined Novartis | Novartis AG |
| 2005–2014 | Various Development & Vaccines Roles | Novartis AG |
| 2014–2018 | Global Head of Drug Development & Chief Medical Officer | Novartis AG |
| Feb 2018–Present | Chief Executive Officer | Novartis AG |
Education
| University | Degree / Program |
|---|---|
| University of Chicago | B.S. Biological Sciences (1997) |
| Harvard Medical School | Doctor of Medicine (M.D.) (2003) |
| Harvard Kennedy School | Master of Public Policy (M.P.P.) (2003) |
Vas Narasimhan Wiki – Age, Family, & More
Vas Narasimhan (age 49) was born on August 26, 1976, in Pittsburgh, Pennsylvania, to Indian-American parents from Tamil Nadu, India. His mother was a nuclear engineer for Public Service Electric and Gas Company, and his father was an executive at Hoeganaes Corporation. Narasimhan’s parents were instrumental in founding the Shri Venkateshwara temple in Penn Hills, Pittsburgh, which he has said was influential in his upbringing.
Narasimhan married Srishti Gupta in 2003 after meeting her at Harvard while organizing an Asian cultural festival. The couple has two children and resides in Basel, Switzerland. He is a vegetarian and has spoken publicly about his practice of yoga and meditation.
Narasimhan is a member of the U.S. National Academy of Medicine and serves on the Board of Fellows of Harvard Medical School. At the 2026 World Economic Forum in Davos, he predicted that AI would deliver a major “payoff for pharma in 7–10 years,” emphasizing the intersection of technology and drug development.
About Novartis
Novartis AG is a Swiss multinational pharmaceutical corporation headquartered in Basel, Switzerland. Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis is one of the world’s largest pharmaceutical companies by revenue. In October 2023, the company completed the spin-off of its generics division, Sandoz, to become a pure-play innovative medicines company.
Novartis focuses on five key therapeutic areas: cardiovascular, immunology, neuroscience, oncology, and hematology. The company’s blockbuster drugs include Entresto (heart failure), Kisqali (breast cancer), Cosentyx (psoriasis/inflammatory), Kesimpta (multiple sclerosis), and Pluvicto (prostate cancer). Novartis operates in over 120 countries and employs approximately 77,000 people worldwide. The company’s shares trade on the SIX Swiss Exchange (NOVN) and the New York Stock Exchange (NVS).
Frequently Asked Questions (FAQ)
Who is the CEO of Novartis?
Vas Narasimhan has been the CEO of Novartis AG since February 2018. He was appointed at age 41, making him one of the youngest-ever leaders of a top-10 global pharmaceutical company. Before becoming CEO, he served as Novartis’s Global Head of Drug Development and Chief Medical Officer.
What is Vas Narasimhan’s salary?
Vas Narasimhan earned total compensation of CHF 24.9 million (~$32.4 million) for 2025, a 30% increase over the prior year. His long-term performance plan payed out at 188% of target — the highest level since he became CEO — driven by Novartis’s record financial performance.
What is Vas Narasimhan’s net worth?
As of 2026, Vas Narasimhan’s estimated net worth is approximately $50–70 million, based on his accumulated compensation, equity holdings in Novartis, and personal investments.
Where is Novartis headquartered?
Novartis AG is headquartered at the Novartis Campus in Basel, Switzerland. The company operates in over 120 countries with approximately 77,000 employees worldwide.
What does Novartis do?
Novartis is a global pharmaceutical company focused on innovative medicines in five therapeutic areas: cardiovascular, immunology, neuroscience, oncology, and hematology. Key products include Entresto, Kisqali, Cosentyx, Kesimpta, and Pluvicto. In 2025, the company reported net sales of $54.5 billion.
Is Vas Narasimhan a doctor?
Yes, Vas Narasimhan holds a Doctor of Medicine (M.D.) from Harvard Medical School. He also earned a Master of Public Policy (M.P.P.) from Harvard Kennedy School, giving him a unique combination of medical and public policy expertise that he has applied to pharmaceutical leadership.
Article last updated: March 2026
Disclaimer: All information presented in this article has been compiled from publicly available sources, including corporate disclosures, annual reports, SEC filings, and reputable news outlets. Net worth figures are estimates and may vary by source. This content is provided for informational purposes only and does not constitute financial or investment advice.